Finance

Beta
Lists
ESLA:NASDAQ
Estrella Immunopharma Inc
$1.12
+2.75%
(+0.030) 1D
Jun 1, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ESLA...
Open
$1.11
High
$1.12
Low
$1.05
Mkt. cap
48.20M
Avg. vol.
34.63K
Volume
51.19K
52-wk high
$3.15
52-wk low
$0.78
EPS
-$0.35
Beta
0.98
Shares outstanding
43.03M
Open
$1.11
High
$1.12
Low
$1.05
Mkt. cap
48.20M
Avg. vol.
34.63K
Volume
51.19K
52-wk high
$3.15
52-wk low
$0.78
EPS
-$0.35
Beta
0.98
Shares outstanding
43.03M
News stories
From sources across the web
About Estrella Immunopharma Inc
CEO-
Employees-
Founded2006
HeadquartersEmeryville, California, United States
SectorBiotechnology
Websiteestrellabio.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
4.66M
4.15M
25.41K
1.40M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
883.73K
648.51K
587.78K
891.79K
Operating expense
5.54M
4.80M
613.20K
2.29M
Total operating expenses
5.54M
4.80M
613.20K
2.29M
Operating income
-5.54M
-4.80M
-613.20K
-2.29M
Other non operating income
-
-
-
-
EBT including unusual items
-5.54M
-4.80M
-613.20K
-2.29M
EBT excluding unusual items
-5.54M
-4.80M
-613.20K
-2.29M
Income tax expense
850.00
-
-25.00
-
Effective tax rate
-0.02%
-
-
-
Other operating expenses
-
-
-
-
Net income
-5.54M
-4.80M
-613.17K
-2.29M
Net profit margin
-
-
-
-
Earnings per share
-0.15
-0.13
-0.01
-
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer